Aesthetic plastic surgery · 2025
Combining Microneedling and Tranexamic Acid for Melasma: A Systematic Review and Meta-Analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Qixuan, Ma Chen, Zhang Ling
Аннотация
BACKGROUND: Tranexamic acid (TXA) has been explored as a potential treatment for melasma, and microneedling (MN) enhances transcutaneous drug delivery. To evaluate the clinical efficacy, patient satisfaction, and safety of microneedling combined with TXA (MN + TXA) in treating melasma compared to alternative treatment modalities.
METHODS: A systematic review and meta-analysis were conducted following PRISMA guidelines. Clinical improvement, patient satisfaction, and adverse events were analyzed using standardized mean differences (SMD) with 95% confidence intervals (CI). The risk of bias was assessed using the RoB 2.0 and ROBINS-I tools.
RESULTS: MN + TXA showed no significant improvement over other treatments in overall clinical outcomes. However, subgroup analysis revealed MN + TXA was significantly more effective than MN alone. Patient satisfaction did not significantly differ between MN + TXA and other treatments. The incidence of adverse events was similar across treatment groups.
CONCLUSION: Compared to other therapies, MN+TXA may be considered a potential option for melasma management. Future large-scale, standardized, multicenter trials directly are essential to confirm its efficacy, safety, and clinical utility.
LEVEL OF EVIDENCE I: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
METHODS: A systematic review and meta-analysis were conducted following PRISMA guidelines. Clinical improvement, patient satisfaction, and adverse events were analyzed using standardized mean differences (SMD) with 95% confidence intervals (CI). The risk of bias was assessed using the RoB 2.0 and ROBINS-I tools.
RESULTS: MN + TXA showed no significant improvement over other treatments in overall clinical outcomes. However, subgroup analysis revealed MN + TXA was significantly more effective than MN alone. Patient satisfaction did not significantly differ between MN + TXA and other treatments. The incidence of adverse events was similar across treatment groups.
CONCLUSION: Compared to other therapies, MN+TXA may be considered a potential option for melasma management. Future large-scale, standardized, multicenter trials directly are essential to confirm its efficacy, safety, and clinical utility.
LEVEL OF EVIDENCE I: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .